Company / Working Capital
Sarepta Therapeutics Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.4B
FY2025
5-year range
$1.4B / $2.3B
FY2021-FY2025
Trend
-38.4%
vs FY2024
Sector context
#30 of 213
Health Care
What the data says
Sarepta Therapeutics's working capital of $1.4B is higher than 86% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $298M in FY2016 to $2.3B in FY2024.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of -7.0%. Top quartile in the Health Care sector.
Declined from $1.9B to $1.4B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -9.4%
- 5-Year CAGR
- -7.0%
- 10-Year CAGR
- -
Sector benchmark
+54.4% above sector average
Key checks
Key Insights
- 5-year CAGR of -7.0%, indicating a declining trend.
- In FY2025, working capital decreased 38.4% year-over-year.
- Ranks #30 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | -38.4% |
| FY2024 | $2.3B | +21.6% |
| FY2023 | $1.9B | -0.6% |
| FY2022 | $1.9B | -9.9% |
| FY2021 | $2.2B | +4.0% |
| FY2020 | $2.1B | +71.8% |
| FY2019 | $1.2B | -3.9% |
| FY2018 | $1.3B | +9.8% |
| FY2017 | $1.1B | +282.6% |
| FY2016 | $298.1M | +83.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026